Comparative Pharmacology
Head-to-head clinical analysis: MAGNESIUM SULFATE IN DEXTROSE 5 IN PLASTIC CONTAINER versus POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5 AND SODIUM CHLORIDE 0 9 IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MAGNESIUM SULFATE IN DEXTROSE 5 IN PLASTIC CONTAINER versus POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5 AND SODIUM CHLORIDE 0 9 IN PLASTIC CONTAINER.
MAGNESIUM SULFATE IN DEXTROSE 5% IN PLASTIC CONTAINER vs POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Magnesium sulfate provides magnesium ions, which are essential for various physiological processes. It acts as a cofactor for enzymatic reactions, stabilizes excitable membranes, and antagonizes calcium entry at the neuromuscular junction, leading to reduced acetylcholine release and muscle relaxation. In the CNS, it may act as a noncompetitive antagonist of NMDA receptors, exerting anticonvulsant effects.
Potassium chloride provides potassium ions essential for maintaining intracellular osmotic pressure, acid-base balance, and nerve impulse transmission. Dextrose 5% provides glucose for cellular metabolism, and sodium chloride 0.9% provides sodium and chloride ions to maintain extracellular fluid volume and osmolality.
1 to 4 g intravenously as a 5% to 20% solution, rate not exceeding 150 mg/min; dosing frequency depends on indication (e.g., preeclampsia/eclampsia: 4-5 g IV loading then 1-2 g/hr infusion; hypomagnesemia: 1-2 g IV over 1-2 hours, may repeat based on serum magnesium levels).
Intravenous infusion, 15 mEq potassium chloride in 5% dextrose and 0.9% sodium chloride at a rate not exceeding 10 mEq/hour; frequency based on serum potassium levels and clinical need.
None Documented
None Documented
Terminal half-life approximately 4-5 hours in normal renal function; prolonged in renal impairment (up to 40 hours).
Not applicable as potassium is an electrolyte with distribution and elimination dependent on body stores and renal function; in healthy individuals, clearance is rapid with no defined terminal half-life, but in renal impairment, half-life extends.
Primarily renal (90-100% as unchanged magnesium). Less than 1% biliary/fecal.
Renal: >90% of potassium intake is excreted by the kidneys, primarily via distal tubular secretion; <10% fecal, minimal biliary.
Category C
Category A/B
Electrolyte
Electrolyte